	US 11,905,318 B2
	Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
Neil R. Cashman, Vancouver (CA); and Steven S. Plotkin, Vancouver (CA)
Assigned to The University of British Columbia, Vancouver (CA)
Filed by The University of British Columbia, Vancouver (CA)
Filed on Sep. 3, 2020, as Appl. No. 17/011,059.
Application 17/011,059 is a continuation of application No. 15/774,707, granted, now 10,774,120, previously published as PCT/CA2016/051303, filed on Nov. 9, 2016.
Claims priority of provisional application 62/393,615, filed on Sep. 12, 2016.
Claims priority of provisional application 62/365,634, filed on Jul. 22, 2016.
Claims priority of provisional application 62/363,566, filed on Jul. 18, 2016.
Claims priority of provisional application 62/253,044, filed on Nov. 9, 2015.
Prior Publication US 2021/0087244 A1, Mar. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/00 (2006.01); C07K 14/00 (2006.01); A61K 38/00 (2006.01); A61K 38/08 (2019.01); A61K 38/10 (2006.01); A61K 38/12 (2006.01); A61K 38/17 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C07K 5/103 (2006.01); C07K 5/117 (2006.01); A61K 47/64 (2017.01); C07K 7/06 (2006.01); C12N 5/10 (2006.01); C07K 7/64 (2006.01); A61P 25/28 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 51/10 (2006.01); G01N 33/68 (2006.01); A61K 49/18 (2006.01); A61K 39/395 (2006.01); A61K 38/07 (2006.01); A61K 47/68 (2017.01); A61K 45/00 (2006.01); A61K 51/08 (2006.01); A61K 47/69 (2017.01); A61K 38/05 (2006.01); A61K 45/06 (2006.01); C07K 7/08 (2006.01); C07K 16/00 (2006.01); C07K 14/435 (2006.01); G01N 33/50 (2006.01); A61L 27/22 (2006.01); A61L 27/34 (2006.01); A61L 31/10 (2006.01); A61L 31/16 (2006.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01)

CPC C07K 14/4711 (2013.01) [A61K 38/1716 (2013.01); A61K 39/0007 (2013.01); A61K 39/39 (2013.01); A61K 47/643 (2017.08); A61K 47/646 (2017.08); A61K 51/1018 (2013.01); A61P 25/28 (2018.01); C07K 5/101 (2013.01); C07K 5/1024 (2013.01); C07K 7/06 (2013.01); C07K 7/64 (2013.01); C07K 16/18 (2013.01); C12N 5/10 (2013.01); G01N 33/6896 (2013.01); A61K 38/00 (2013.01); A61K 38/05 (2013.01); A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 38/12 (2013.01); A61K 39/00 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 45/05 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6921 (2017.08); A61K 49/1818 (2013.01); A61K 49/1866 (2013.01); A61K 51/088 (2013.01); A61K 51/10 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/6081 (2013.01); A61K 2300/00 (2013.01); A61L 27/227 (2013.01); A61L 27/34 (2013.01); A61L 29/085 (2013.01); A61L 29/16 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); C07K 7/08 (2013.01); C07K 14/435 (2013.01); C07K 16/00 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); G01N 33/5058 (2013.01); G01N 2333/4709 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/387 (2013.01)]

19 Claims

1. A cyclic compound comprising: an A-beta peptide and a linker, the A-beta peptide consisting of amino acids HHQK (SEQ ID NO: 1), wherein the linker is covalently coupled to the A-beta peptide N-terminus residue and the A-beta C-terminus residue, wherein the linker consists of amino acids GCG or CGC.